| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0025 | MTCO1P5 | laryngeal squamous cell carcinoma | microarray, qPCR etc. | LSCC tissue | down-regulated | expression | AC026166.2-001 and RP11-169D4.1-001 were distinctly dysregulated, with AC026166.2-001 exhibiting lower expression in cancer tissues and RP11-169D4.1-001 higher expression. We verified that both AC026166.2-001 and RP11-169D4.1-001 were expressed at a lower level in cervical lymph nodes compared with paired laryngeal cancer tissues and paired normal tissues. RP11-169D4.1-001 levels were positively correlated with lymph node metastasis. | 25243407 | Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | up-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
| EL0556 | H19 | laryngeal squamous cell carcinoma | knockdown | LSCC patients | up-regulated | N/A | The inhibition of LSCC progression induced by H19 knockdown required the activity | 26872375 | |
| EL0578 | HOTAIR | laryngeal squamous cell carcinoma | N/A | N/A | N/A | expression | Inspired observed that HOTAIR was higher expressed in primary LSCC than in adjacent noncancerous tissues. It is noteworthy that over-expression of HOTAIR was related to poor differentiation, lymph node metastasis, or advanced clinical stages of LSCC. The results suggested that HOTAIR promotes the malignant progression of LSCC. | 24817925 | LncRNADisease |
| EL0578 | HOTAIR | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | up-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
| EL0578 | HOTAIR | laryngeal squamous cell carcinoma | qPCR, in vitro knockdown etc. | cell lines (Hep-2) | up-regulated | N/A | HOTAIR levels were significantly higher in LSCC than in corresponding adjacent non-neoplastic tissues, and patients with poor histological grade or advanced clinical stage had higher HOTAIR expression. PTEN methylation was significantly reduced in Hep-2 cells depleted of HOTAIR. Taken together, these results suggest that the oncogenic role of HOTAIR in LSCC is related to promotion of PTEN methylation. | 23141928 | Lnc2Cancer |
| EL0578 | HOTAIR | laryngeal squamous cell carcinoma | qPCR, Western blot etc. | blood (serum) | up-regulated | N/A | The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with laryngeal squamous cell carcinomaLSCC than those with vocal cord polyps; The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without. | 25099764 | LncRNADisease Lnc2Cancer |
| EL0853 | MALAT1 | laryngeal squamous cell carcinoma | N/A | N/A | N/A | expression | The result suggested that the MALAT1 was up-regulated in primary LSCC compared with adjacent non-cancerous tissues. | 24817925 | LncRNADisease |
| EL0853 | MALAT1 | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | up-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
| EL0879 | MIR21 | laryngeal squamous cell carcinoma | N/A | N/A | N/A | N/A | The expression of exosomal miR-21 and HOTAIR was significantly higher in patients with laryngeal squamous cell carcinomaLSCC than those with vocal cord polyps; The patients with lymph node metastasis had higher serum exosomal miR-21 and HOTAIR expressions than those without. | 25099764 | LncRNADisease Lnc2Cancer |
| EL1135 | LINC01537 | laryngeal squamous cell carcinoma | microarray, qPCR etc. | LSCC tissue | up-regulated | expression | AC026166.2-001 and RP11-169D4.1-001 were distinctly dysregulated, with AC026166.2-001 exhibiting lower expression in cancer tissues and RP11-169D4.1-001 higher expression. We verified that both AC026166.2-001 and RP11-169D4.1-001 were expressed at a lower level in cervical lymph nodes compared with paired laryngeal cancer tissues and paired normal tissues. RP11-169D4.1-001 levels were positively correlated with lymph node metastasis. | 25243407 | Lnc2Cancer |
| EL1171 | RRP1B | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | down-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |
| EL1241 | SRA1 | laryngeal squamous cell carcinoma | qPCR etc. | LSCC tissue | down-regulated | expression | We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. | 25257554 | Lnc2Cancer |